Want to see JP:4571 full AI Analyst Report?

NanoCarrier Co., Ltd. (4571) Price & Analysis

2 Followers

4571 Stock Chart & Stats

¥134.00

-¥1.00(-0.68%)

At close: Jan 08 4:00 PM EST

¥134.00

-¥1.00(-0.68%)

Day’s Range― - ―

52-Week Range¥95.00 - ¥254.00

Previous CloseN/A

Volume236.30K

Average Volume (3M)2.35M

Market Cap

¥8.40B

Enterprise Value¥4.90B

Total Cash (Recent Filing)¥3.40B

Total Debt (Recent Filing)¥540.24M

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.48

Shares Outstanding83,221,756

10 Day Avg. Volume484,410

30 Day Avg. Volume2,345,523

Financial Highlights & Ratios

PEG Ratio-1.32

Price to Book (P/B)3.10

Price to Sales (P/S)63.30

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary DDS PlatformNanoCarrier’s micellar nanoparticle DDS is a durable competitive asset: it improves therapeutic delivery, is applicable across oncology programs, and creates a basis for recurring licensing and milestone income as partners adopt the tech, supporting long-term revenue potential.

Very High Gross MarginsSustained gross margins near 72–88% indicate attractive unit economics from the platform or contracted work. High incremental margins help the company leverage top-line growth into operating leverage over time if R&D and SG&A are controlled, improving long-term path to profitability.

Revenue Rebound & Licensing ModelA 50% YoY revenue rebound combined with a business model centered on collaborations, upfronts, milestones and royalties provides diversified, scalable revenue streams that can persist across cycles and reduce dependence on single-product commercialization events.

Bears Say

Persistent Negative Operating Cash FlowConsistent negative operating cash flow shows the core operations consume cash rather than fund themselves. Over months this forces reliance on external financing, constrains R&D planning, and increases dilution or refinancing risk if cash burn remains unresolved.

Sustained Operating And Net LossesRepeated operating and net losses indicate structural shortfall between recurring costs and revenue today. Continued negative profitability erodes equity, delays break-even, and makes long-term planning and partner negotiations more sensitive to funding availability.

Rising Debt And Shrinking EquityMeaningful debt growth with falling assets/equity reduces financial flexibility and increases fixed obligations. If revenues or milestone timing falter, higher leverage raises refinancing and interest risks, constraining investment in development and licensing activities.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

4M ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

10M ago

4571 FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was ¥95.00 and its highest was ¥254.00 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is ¥8.40B.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥3.84 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.84.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 83,221,756 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -¥3.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4571

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.